[go: up one dir, main page]

EE200200578A - Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid - Google Patents

Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid

Info

Publication number
EE200200578A
EE200200578A EEP200200578A EEP200200578A EE200200578A EE 200200578 A EE200200578 A EE 200200578A EE P200200578 A EEP200200578 A EE P200200578A EE P200200578 A EEP200200578 A EE P200200578A EE 200200578 A EE200200578 A EE 200200578A
Authority
EE
Estonia
Prior art keywords
antihypertensive
agent
angiogenic agents
therapeutic combinations
angiogenesis
Prior art date
Application number
EEP200200578A
Other languages
English (en)
Estonian (et)
Inventor
Owen Curwen Jon
James Ogilvie Donald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200578A publication Critical patent/EE200200578A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP200200578A 2000-04-05 2001-04-02 Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid EE200200578A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008269.3A GB0008269D0 (en) 2000-04-05 2000-04-05 Combination chemotherapy
PCT/GB2001/001522 WO2001074360A1 (en) 2000-04-05 2001-04-02 Therapeutic combinations of antihypertensive and antiangiogenic agents

Publications (1)

Publication Number Publication Date
EE200200578A true EE200200578A (et) 2004-06-15

Family

ID=9889176

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200578A EE200200578A (et) 2000-04-05 2001-04-02 Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid

Country Status (29)

Country Link
US (1) US7829573B2 (xx)
EP (3) EP1272186B1 (xx)
JP (1) JP2003528917A (xx)
KR (2) KR20080034523A (xx)
CN (1) CN1431902A (xx)
AT (1) ATE355065T1 (xx)
AU (2) AU2001244386B2 (xx)
BR (1) BR0109729A (xx)
CA (1) CA2401854A1 (xx)
CY (1) CY1107615T1 (xx)
CZ (1) CZ299410B6 (xx)
DE (1) DE60126923T2 (xx)
DK (1) DK1272186T3 (xx)
EE (1) EE200200578A (xx)
ES (1) ES2280349T3 (xx)
GB (1) GB0008269D0 (xx)
HU (1) HUP0300426A2 (xx)
IL (1) IL151503A0 (xx)
IS (2) IS2455B (xx)
MX (1) MXPA02009743A (xx)
NO (2) NO323467B1 (xx)
NZ (2) NZ534455A (xx)
PL (1) PL357605A1 (xx)
PT (1) PT1272186E (xx)
RU (1) RU2002129353A (xx)
SI (1) SI1272186T1 (xx)
SK (1) SK14302002A3 (xx)
WO (1) WO2001074360A1 (xx)
ZA (1) ZA200206959B (xx)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
HK1049664B (en) * 1999-11-05 2006-11-10 Genzyme Corporation Quinazoline derivatives as vegf inhibitors
ATE300303T1 (de) 2000-03-06 2005-08-15 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
BR0109828A (pt) * 2000-04-07 2002-12-17 Astrazeneca Ab Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
RU2365588C2 (ru) 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
DE60311788T2 (de) * 2002-04-16 2007-11-22 Astrazeneca Ab Kombinationstherapie zur behandlung von krebs
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
DK2305301T3 (en) * 2002-07-19 2015-04-13 Beth Israel Hospital Methods for the treatment of pre-eclampsia
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
JP4593464B2 (ja) 2002-11-04 2010-12-08 アストラゼネカ アクチボラグ Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CA2529409A1 (en) * 2003-06-18 2004-12-29 Angiogene Pharmaceuticals Limited Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
AU2004255022B2 (en) * 2003-07-10 2007-08-23 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
JP4503022B2 (ja) * 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1740170A2 (en) * 2004-03-23 2007-01-10 AstraZeneca AB Combination therapy with azd2171 and platinum anti-tumour agent
EP1737452A1 (en) * 2004-04-06 2007-01-03 Angiogenetics Sweden AB Angiogenesis-affecting compounds and methods of use thereof
US20070142308A1 (en) * 2005-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods for use thereof
US20070142433A1 (en) * 2004-04-06 2007-06-21 Helmut Augustin Angiogenesis-affecting compounds and methods of use thereof
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US20060067937A1 (en) 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
CA2578956A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Combination comprising zd6474 and an imatinib
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
BRPI0519096A2 (pt) * 2004-12-15 2008-12-23 Beth Israel Hospital Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
WO2006086544A2 (en) 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
CN101137380A (zh) * 2005-03-09 2008-03-05 默克公司 喹唑啉酮t-型钙通道拮抗剂
JP2009500384A (ja) * 2005-07-06 2009-01-08 アストラゼネカ アクチボラグ 併用療法
MX2008001838A (es) 2005-08-08 2008-04-09 Pfizer Sales y polimorfos de un inhibidor de vegf-r.
RU2414924C2 (ru) 2005-08-12 2011-03-27 Ридженерон Фармасьютикалз, Инк. Способы лечения заболеваний антагонистами vegf
HRP20110360T1 (hr) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija zd6474 i pemetrekseda
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
DK2131841T3 (da) * 2007-01-30 2012-10-15 Avigen Inc Fremgangsmåder til behandling af akut smerte
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
CA2684938A1 (en) * 2007-05-02 2008-11-13 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
CA2692783A1 (en) * 2007-07-10 2009-01-15 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
CA2730773A1 (en) 2008-07-14 2010-01-21 Martha Karen Newell Methods and products for treating proliferative diseases
ES2557407T3 (es) 2010-03-01 2016-01-25 Tau Therapeutics Llc Procedimiento de imaginología de una enfermedad
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN103110614B (zh) * 2013-01-18 2015-02-18 杭州雷索药业有限公司 舒洛地尔在制备抗血管生成类药物中的应用
AU2014219024B2 (en) * 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
CN106572988B (zh) 2014-04-08 2022-04-08 卫理公会医院 Inos抑制性组合物及其作为乳腺癌治疗剂的用途
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
US10265111B2 (en) 2016-04-26 2019-04-23 Medtronic Holding Company Sárl Inflatable bone tamp with flow control and methods of use
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
WO2020028007A1 (en) * 2018-07-31 2020-02-06 Colorado State University Research Foundation Compositions, methods and uses for modulating the tumor microenvironment to enhance antitumor immunity
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11484355B2 (en) 2020-03-02 2022-11-01 Medtronic Holding Company Sàrl Inflatable bone tamp and method for use of inflatable bone tamp

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT880508E (pt) * 1996-02-13 2003-07-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
IL125954A (en) * 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
DE69734149T2 (de) * 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
CA2263479A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as vegf
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2275708A1 (en) 1996-12-23 1998-07-02 Cambridge University Technical Services Limited Diagnosis and treatment of pathological pregnancies
US6294532B1 (en) * 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
ATE405651T1 (de) * 1998-03-17 2008-09-15 Genentech Inc Zu vegf und bmp1 homologe polypeptide
US6191144B1 (en) * 1998-08-17 2001-02-20 Warner-Lambert Company Method of using angiotensin converting enzyme inhibitor to stimulate angiogenesis
AU5910599A (en) 1998-09-09 2000-03-27 Scios Inc. Treatment of microvascular angiopathies
EP1146891B1 (en) * 1999-01-15 2006-12-20 Medstar Research Institute Therapy of restenosis and atherosclerosis with a soluble vegf receptor and angiopoeitin-1
CZ305827B6 (cs) * 1999-02-10 2016-03-30 Astrazeneca Ab Indolové deriváty
HK1049664B (en) * 1999-11-05 2006-11-10 Genzyme Corporation Quinazoline derivatives as vegf inhibitors
AU2001280546B2 (en) * 2000-07-13 2005-10-20 Alteon, Inc. Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
JP2006502132A (ja) 2002-08-09 2006-01-19 アストラゼネカ アクチボラグ 癌の治療における血管内皮細胞増殖因子受容体の阻害薬ｚｄ６４７４と放射線療法との併用
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
PT1592423E (pt) * 2003-02-13 2011-06-16 Astrazeneca Ab Terapia de combinação de zd6474 com 5-fu e/ou cpt-11
GB0310401D0 (en) 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
AU2004255022B2 (en) 2003-07-10 2007-08-23 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0406445D0 (en) 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1740170A2 (en) * 2004-03-23 2007-01-10 AstraZeneca AB Combination therapy with azd2171 and platinum anti-tumour agent
GB0406446D0 (en) 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
CA2578956A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Combination comprising zd6474 and an imatinib
MX2007003506A (es) 2004-09-27 2007-05-10 Aztrazeneca Ab Terapia de combinacion de cancer que comprende azd2171 e imatinib.
GB0424339D0 (en) 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP2009500384A (ja) 2005-07-06 2009-01-08 アストラゼネカ アクチボラグ 併用療法
NZ569787A (en) * 2005-12-15 2011-07-29 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
KR20080077678A (ko) * 2005-12-22 2008-08-25 아스트라제네카 아베 Ａｚｄ2171 및 페메트렉시드의 조합물
HRP20110360T1 (hr) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija zd6474 i pemetrekseda
US20100092466A1 (en) 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
EP2134340A1 (en) 2007-04-13 2009-12-23 AstraZeneca AB Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii

Also Published As

Publication number Publication date
DE60126923T2 (de) 2007-10-31
DK1272186T3 (da) 2007-05-21
SK14302002A3 (sk) 2003-05-02
CY1107615T1 (el) 2013-03-13
IS2455B (is) 2008-11-15
PL357605A1 (en) 2004-07-26
EP1658849A3 (en) 2009-02-18
KR20030007491A (ko) 2003-01-23
WO2001074360A1 (en) 2001-10-11
NO20024814D0 (no) 2002-10-04
GB0008269D0 (en) 2000-05-24
KR20080034523A (ko) 2008-04-21
IS6557A (is) 2002-09-20
US7829573B2 (en) 2010-11-09
CN1431902A (zh) 2003-07-23
ATE355065T1 (de) 2006-03-15
RU2002129353A (ru) 2004-03-20
EP1790340A2 (en) 2007-05-30
NZ520938A (en) 2005-08-26
EP1272186A1 (en) 2003-01-08
NO326277B1 (no) 2008-10-27
CA2401854A1 (en) 2001-10-11
IL151503A0 (en) 2003-04-10
SI1272186T1 (sl) 2007-06-30
NO20062050L (no) 2001-10-08
AU4438601A (en) 2001-10-15
BR0109729A (pt) 2003-02-04
EP1790340A3 (en) 2009-03-18
MXPA02009743A (es) 2003-03-27
NO20024814L (no) 2002-11-12
HUP0300426A2 (hu) 2003-06-28
ES2280349T3 (es) 2007-09-16
EP1272186B1 (en) 2007-02-28
US20030144298A1 (en) 2003-07-31
ZA200206959B (en) 2003-12-01
CZ299410B6 (cs) 2008-07-16
EP1658849A2 (en) 2006-05-24
KR100849149B1 (ko) 2008-07-31
AU2001244386B2 (en) 2005-01-27
DE60126923D1 (de) 2007-04-12
JP2003528917A (ja) 2003-09-30
NO323467B1 (no) 2007-05-21
NZ534455A (en) 2007-01-26
PT1272186E (pt) 2007-04-30
IS8726A (is) 2008-04-16

Similar Documents

Publication Publication Date Title
EE200200578A (et) Antihüpertensiivsete ja antiangiogeensete ainete terapeutilised kombinatsioonid
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
DE60111539D1 (de) Pharmazeutische zusammensetzung enthaltend ein 5-aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
BR9914360A (pt) N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
EA200700777A1 (ru) Содержащие октенидин таблетки для рассасывания, предназначенные для лечения воспалительных заболеваний полости рта и глотки
SE0000303D0 (sv) Novel compounds
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
DE60031385D1 (de) Pharmazeutische Zusammensetzungen von Antibiotika und Fruktan-Gemische
DE60122764D1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
WO2003066806A3 (en) Therapeutic use of aziridino compounds
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria